These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33243967)

  • 21. Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
    Chang CL; Tsai HC; Lin WC; Chang JH; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Radiother Oncol; 2017 Oct; 125(1):73-79. PubMed ID: 28923576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.
    Liu C; Sun H; Huang W; Wang Z; Fu C; Han D; Zhao Q; Wu X; Li B
    Front Immunol; 2023; 14():1193394. PubMed ID: 37325650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
    Chi D; Chen B; Guo S; Bai K; Ma H; Hu Y; Li Q; Zhu Y
    Aging (Albany NY); 2021 Mar; 13(6):8408-8420. PubMed ID: 33713398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and cost-effectiveness analysis of pretreatment percutaneous endoscopic gastrostomy in unresectable locally advanced esophageal cancer patients treated with concurrent chemoradiotherapy (GASTO 1059).
    Ai X; Zhang P; Xie X; Qiu B; Zhu Y; Zhao L; Xi M; Wu Y; Guo S; Guo J; Liu F; Wang D; Chen N; He Q; Hu Y; Liu M; Ding Z; Liu H
    Cancer Med; 2023 Jul; 12(14):15000-15010. PubMed ID: 37326436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the Clinical Outcomes of Esophagectomy and Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.
    Lee MH; Park MI; Lee JW; Jung K; Kim JH; Kim SE; Moon W; Park SJ
    Korean J Gastroenterol; 2024 Mar; 83(3):102-110. PubMed ID: 38522853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.
    Liu A; Wang Y; Wang X; Zhu L; Nie Y; Li M
    Radiat Oncol; 2021 Oct; 16(1):195. PubMed ID: 34600574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Frailty on Treatment Outcome in Patients With Locally Advanced Esophageal Cancer Undergoing Concurrent Chemoradiotherapy.
    Huang YH; Hung YS; Lai CC; Ho MM; Yeh KY; Yang C; Lu CH; Tseng CK; Tsang NM; Hung CY; Hsueh SW; Chang PH; Ho YW; Lin YC; Chou WC
    Anticancer Res; 2021 Oct; 41(10):5213-5222. PubMed ID: 34593474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy.
    Pao TH; Chang WL; Chiang NJ; Chang JS; Lin CY; Lai WW; Tseng YL; Yen YT; Chung TJ; Lin FC
    Radiat Oncol; 2020 Sep; 15(1):221. PubMed ID: 32962730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
    Yao B; Tan B; Wang C; Song Q; Wang J; Guan S; Jia Y; Ma Y; Huang X; Sun Y; Cheng Y
    Ann Surg Oncol; 2016 Jul; 23(7):2367-72. PubMed ID: 26932711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
    Ni WJ; Deng W; Xiao ZF; Zhou ZM; Wang X; Chen DF; Feng QF; Liang J; Lyu JM; Bi N; Deng L; Zhang T; Wang WQ; Xue Q; Gao SG; Mu JW; Mao YS; Wang DL; Zhao J; Gao YS; Huang JF; Tan FW; Zhao L; Lyu F; Zhang GC
    Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):295-302. PubMed ID: 31014056
    [No Abstract]   [Full Text] [Related]  

  • 33. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.
    Lyu J; Li T; Wang Q; Li F; Diao P; Liu L; Li C; Lang J
    Radiat Oncol; 2018 Nov; 13(1):233. PubMed ID: 30477531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma.
    Ni W; Yang J; Deng W; Xiao Z; Zhou Z; Zhang H; Chen D; Feng Q; Liang J; Lv J; Wang X; Wang X; Zhang T; Bi N; Deng L; Wang W
    BMC Cancer; 2020 Feb; 20(1):144. PubMed ID: 32087687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.
    Zeng J; Cui X; Cheng L; Chen Y; Du X; Sheng L
    Cancer Radiother; 2021 Jul; 25(5):441-446. PubMed ID: 33958272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of Hematoxylin and eosin staining tumor-infiltrating lymphocytes (H&E-TILs) in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy.
    Zheng J; Zhang H; Li S; Kang Z; Zheng F; Yao Q; Zhang X; Wu Z; Wang J; Fang W; Li J; Chen G; Chen Y; Chen M
    BMC Cancer; 2023 Dec; 23(1):1193. PubMed ID: 38053017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective analysis of safety profile of high-dose concurrent chemoradiotherapy for patients with oesophageal squamous cell carcinoma.
    Ren X; Wang L; Han C; Ren L
    Radiother Oncol; 2018 Nov; 129(2):293-299. PubMed ID: 30270099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of intensity-modulated radiotherapy combined with chemotherapy and prognostic factors in patients with locally advanced oesophageal cancer.
    Ou Y; Li H; Yang D; Suo L
    Adv Med Sci; 2024 Mar; 69(1):125-131. PubMed ID: 38438081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A nomogram based on pretreatment CT radiomics features for predicting complete response to chemoradiotherapy in patients with esophageal squamous cell cancer.
    Luo HS; Huang SF; Xu HY; Li XY; Wu SX; Wu DH
    Radiat Oncol; 2020 Oct; 15(1):249. PubMed ID: 33121507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.
    Shi Z; Zhu X; Ruan C; Wei G; Li J; Qiu H; Gao L; Cai G; Zhangcai Y; Li B; Wang J; Gong Y; Chen J; Zhao W; Wu Y; Ke S; Chen Y
    JAMA Netw Open; 2022 Dec; 5(12):e2244619. PubMed ID: 36454568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.